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Distinct linker sequences were introduced into the protease-sensitive V, domain of protein kinase 
C-a and the mutant proteins were expressed in COS-1 cells. Partially purified preparations of these 
mutants were functionally similar to wild-type protein kinase C-a, however their susceptibility to 
m-calpain was quite distinct, with one mutant being insensitive to cleavage. The three mutants, after 
expression in COS-1 cells, were found to behave in a manner indistinguishable from wild-type 
protein kinase C-a with respect to subcellular distribution, acute responses to 12Otetradecanoyl- 
phorbol 13-acetate and 3 2-0-tetradecanoyl-phorbol-13-acetate-induced down-regulation. The data 
imply that down-regulation of protein kinase C-a is likely to involve a general degradative process 
rather than cleavage by a site-specific protease. 
The protein-kinase-C (PKC) gene family is comprised of 
at least nine genes [l-31. Most, but not all of these protein 
kinases share a dependence upon diacylglycerol and phos- 
pholipid for activity. Activated PKC is thus membranekesi- 
cle associated both in vitro and in vivo. Chronic activation of 
PKC in vivo through the action of phorbol esters frequently 
leads to a decrease in steady-state expression levels. This 
phenomenon, down-regulation, is due to an increased rate of 
proteolysis [4-61, which can occur in the absence of any 
change in the rate of synthesis. Thus in vivo data are consis- 
tent with the notion that PKC in its active state is in a more 
open conformation and is thus accessible to proteases. Em- 
pirical evidence for an open conformation and exposure of a 
proteolytically sensitive domain has come both from studies 
on sensitivity to the calcium-activated neutral proteases 
(m-calpain and p-calpain) and their sites of action [7], and 
through studying the binding of a monoclonal antibody [8]. 
These data demonstrate that the variable region, V3, between 
the conserved regulatory domain and the catalytic domain 
(Fig. l) ,  is the site of protease cleavage and that this V, re- 
gion is more accessible in PKC following binding of its acti- 
vators. The altered exposure of the V, region on activation 
provides one explanation for the down-regulation elicited in 
vivo by chronic exposure to phorbol esters. Such a passive 
effect of phorbol esters in inducing down-regulation is con- 
sistent with the observation that kinase-deficient PKC mu- 
tants can also be down-regulated [9, lo], i.e. intramolecular 
autophosphorylation is not essential for down-regulation to 
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occur. (It should be noted that in other contexts, such kinase- 
deficient-mutants can show altered properties [ll]). How- 
ever, these kinase-deficient mutants have not been expressed 
in PKC-deficient conditions. Thus, while a kinase-negative 
PKC-a can be down-regulated when expressed in COS cells, 
these cells also retain an endogenous wild-type PKC-a that 
itself shows a typical down-regulation response and may be 
responsible for driving such a response for the mutant. 
As a first step in assessing the mechanism and role of 
proteolysis/down-regulation in PKC action, it would be de- 
sirable to define the protease(s) involved in this process. The 
investigations described in this study were designed to ad- 
dress this issue through mutagenesis of the proteolytically 
sensitive hinge domain of PKC-a. The results imply that cal- 
pain is not responsible for down-regulation. Furthermore, it 
is unlikely that any single, sequence-specific protease is in- 
volved. 
MATERIALS AND METHODS 
Materials 
Chemicals and biochemicals were from Sigma or BDH 
unless indicated. [y-32P]ATP and ECL reagents were from 
Amersham International. Calpain (m-form) was purified as 
described previously [ 121. 
Preparation and expression of PKC-a V, domain mutants 
The V, domain of bovine PKC-a[13] between the SacI 
site (bp 953) and BstXI site (bp 1041) was replaced with one 
of three PCR fragments derived from predicted hinge regions 
of PKC-P, [14], PLC-S, [15] or p85a [16]; the constructions 
are summarised in Fig. 1. The fragments were obtained from 
the respective cloned cDNAs by PCR employing sense and 
antisense oligonucleotides flanked by SacI and BstXI sites, 
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Fig. 1. Construction of PKC V, domain mutants. (A) PCK-a is 
shown delineating the variable (V) and conserved (C) domains. The 
third variable domain (V,) is shown in detail alongside the three 
sequences with which it was replaced. These sequences are derived 
from the indicated cDNAs and are from predicted interdomain linker 
regions. PLC-pz, V,p2; PLC-81. V,6,: p85a, p85V3. (B) The strategy 
employed for creation of the V, mutations. The mutant V, sequences 
were obtained from the respective cDNAs by PCR and subcloned 
as SacI(S) -RstXI(X) fragments into a BamHI(B)-SmaI(M) frag- 
ment of PKC-K from which the internal Sacl-BstXI fragment had 
been removed (2).  This yielded mutated clones ( 5 )  which were 
checked by sequence analysis prior to subcloning back into a 
BarnHI-Srnnl restricted full-length PCK-a (3),  yielding the full- 
length mutants of PKC-a (6). 
respectively. The products were cut at these restriction sites 
and cloned into the Bluescript plasmid (Pharmacia) and se- 
quenced. The various mutant fragments were subcloned as 
Sac1 -BstXI fragments back into a wild-type PCK-a 
BamHI-SmaT fragment in Bluescript also restricted with 
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Fig. 2. Partial purification of wild-type and V, domain mutants 
of PKC-a. COS-1 cells were transfected with each construct as indi- 
cated in the individual panels and extracts were fractionated by chro- 
matography on heparin-Sephdrose (see Materials and Methods sec- 
tion). The activity was determined using histone 111-S as a substrate 
either in the absence (0) or presence (0) of phosphoiipidTPA. One 
of four similar experiments is shown. wt, wild-type. 
Sac1 and BstXI. The full-length mutants were created by re- 
placing the wild-type PCK-a BamHI -SmaI fragment with 
each of the mutant fragments. This procedure yielded the 
phospholipase-C-P,-derived mutant PCK-a V$,, the phos- 
pholipase-C-&,-derived mutant PCK-a V,& and the p85a-de- 
rived mutant PKC-a pSSV,. The full-length wild-type and 
mutant PKC-a species were subcloned into the PKS-1 ex- 
pression vector [17]. Culture and transfection of COS-1 cells 
were as described previously [ 181. 
Extraction and fractionation or wild-type 
and mutant PKC 
PKC-a and the V, mutants were extracted either directly 
into Laemmli sample buffer for analysis by SDSPAGE [19], 
or were scraped into 20 mM Tris/HCI, pH 7.5, 5 mM EDTA, 
5 mM EGTA, 0.3% (by vol.) 2-mercaptoethanol, 10 mM 
benzamidine, 50 pg/ml phenylmethylsulfonyl fluoride, 
100 pg/ml leupeptin, homogenised in a Dounce and fraction- 
ated by centrifugation as described previously [20]. The frac- 
tionation yielded soluble (cytosolic), neutral detergent solu- 
ble (particulate), and detergent insoluble (cytoskeleton) frac- 
tions. 
In experiments investigating calpain sensitivity and func- 
tional integrity of the proteins, the transfected cells were 
lysed directly in 20 mM Tris/HCI, pH 7.5, 5 mM EDTA, 
5 mM EGTA, 0.3% (by vol.) 2-mercaptoethanol, 10 mM 
benzamidine, 50 pg/ml phenylmethylsulfonyl fluoride, 
100 pg/ml leupeptin, 1% (by vol.) Triton X-100 and the ex- 
tract was cleared by centrifugation in a microfuge for 10 min 
at 4°C. The supernatant was loaded onto a 1 ml heparin- 
Sepharose column (Pharmacia) attached to an FPLC instru- 
ment. The bound protein was eluted with a linear gradient of 
0-1 .0 M NaCl in 20 mM Tris/HCl, 2 mM EDTA, 10 mM 
benzamidine, 0.3% 2-mercaptoethanol, 0.1 % (by vol.) Triton 
X-100. PKC activity was determined using the substrate his- 
tone 111-S as described previously [21]. 
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Fig. 3. m-calpain sensitivity of wild-type and V, domain mutants 
of PKC-a. PCK-a (mutants and wild-type) were partially purified 
by chromatography on heparin-Sepharose. Equivalent amounts of 
activity (1.1 units) were subjected to calpain cleavage at 30°C and 
samples were taken and processed for Westem-blot analysis. Initial 
rates of cleavage are shown for 0, 5 ,  15 min for wild-type PKC-a 
(lanes 1 -3), PCK-a VJ2 (lanes 4-6), PKC-a V,6, (lanes 7-9) and 
PCK-a p85V, (lanes 10-12). The full-length intact PKC is indicated 
(F) in each panel. Where observed, a catalytic domain fragment is 
indicated (+). This is one of four similar sets of analysis from dif- 
ferent preparations of PKC. 
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Fig. 5. Subcellular fractionation of transfected COS-1 cells. The 
expression of (A) wild-type PKC-a and (B) V,p, mutant of PKC-a 
was examined in fractions derived from transfected COS-1 cells. 
Cultures were either untreated (0) or treated with TPA for 15 min 
or 24 h as indicated. Extracts were separated into soluble (SN), Tri- 
ton X-100 soluble (TS) and Triton X-100 insoluble (TI) fractions as 
described in the Materials and Methods section. Expressed PKC-a 
was visualised by Westem-blot analysis. The upper panels in both 
(A) and (B) show long exposures in order to allow visualisation of 
the residual antigen present on long-term exposure to TPA (this is 
not visible with a short exposure). Similar results were obtained with 
the PCK-a V,d, and PKC-a p8SV, mutants. 
Fig. 4. Expression and down-regulation of wild-type PKC-a and 
V, domain mutants. The wild-type (wt) and V3 domain mutants 
were transfected into COS-1 cells and 48 h later, following culture 
in the absence (-) or presence (+) of TPA, were extracted for West- 
ern-blot analysis as described in the Materials and Methods section. 
The immunoreactive species observed are = 80 kDa for all PKC-a 
constructs; in each case, the bulk of the immunoreactive protein is 
lost on TPA treatment. b2, V,b2; a,, V,d,; p85, p8S V,; wt, wild- 
type. 
PKC was detected with antisera to the C-terminus of PCK-a 
~211 using the ECL system for detection. 
RESULTS 
Mutations in the V, domain of PCK-a were introduced 
as outlined in Fig. 1. These mutations were designed on the 
premise that the mutant sequences were derived from pro- 
teins which, like PKC, are active at the membrane and them- 
Proteolysis of wild-type and mutant PKC 
PKC-a and V, mutants were isolated by chromatography 
on heparin -Sepharose as described above. The fractions 
with highest activity were employed to follow the suscep- 
tibility to calpain cleavage. The ions for calpain treatment 
were initially optimised on purified PKC-P, (data not shown) 
and were as follows: 80 yl sample contained 60 yl partially 
purified PKC-a or PKC-a V, mutant, 10 pl calpain (2  mg/ml 
diluted tenfold in 20 mM Tris/HCl, pH 7.5,O.l mg/ml bovine 
serum albumin, 1 mM dithiothreitol) or dilution buffer and 
10 yl 40 mM Ca”. Incubations were carried out at 30°C for 
the times indicated in the figure legends and reactions were 
stopped by addition of an equal volume of Laemmli sample 
buffer [19] to an aliquot of reaction mixture. Samples were 
boiled, the proteins were separated by SDS/PAGE [19] and 
selves are not known to be susceptible to proteolysis within 
these specific sequences. On transfection, all three V, domain 
mutants were found to be expressed in COS-1 cells, at a level 
comparable to that of the transfected wild-type PKC-a. 
To assess directly the potential role of calpain in the pro- 
cess of down-regulation, wild-type and V,mutant forms of 
PCK-a were purified by heparin-Sepharose chromatography 
for proteolytic studies. All three V, mutant proteins behaved 
like wild-type PKC-a and showed typical phosphatidylserine 
12-0-tetradecanoyl-phorbol 13-acetate (TPA)-dependent his- 
tone kinase activity (Fig. 2). This provides further evidence 
that the V, region of PCK-a acts as a ‘spacer’, conferring no 
apparent functional property. 
The partially purified PKC-a and V, mutants were sub- 
jected to proteolysis by m-calpain (Fig. 3). This provided evi- 
dence for a hierarchy of sensitivity to m-calpain cleavage. 
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with the pXSV, mutant (Fig. 3, lanes 10-12) more suscepti- 
ble than wild-type PKC-a (lanes 1-3) and the V,6, mutant 
much less sensitive than wild-type PKC-a, but still cleaved 
at a slow rate (Fig. 3, lanes 7-9). The product of cleavage 
for this latter mutant had molecular mass 52 kDa compared 
to 47 kDa for the wild-type PKC-a and p85V, mutant. By 
contrast, the PKC-a V$, mutant was insensitive to proteoly- 
sis by m-calpain (lanes 4-6). 
After establishing the hierarchy of sensitivity to m-cal- 
pain cleavage, the wild-type PKC-rx and V, mutants were fur- 
ther investigated in COS cells to determine their suscep- 
tibility to TPA-induced down-regulation. Transfected COS 
cells were exposed to TPA (200 nM) for 24 h prior to frac- 
tionation and the PKC content was analysed. It is evident 
that none of the altered V, domains confer down-regulation 
insensitivity (Fig. 4). The behaviour of the V, domain mu- 
tants was further investigated with respect to their subcellular 
localisation. Like the wild-type PCK-a, all mutants were 
found distributed between the cytosol, Triton X-100 soluble 
and Triton insoluble fractions (Fig. 5 ; data not shown). Upon 
acute TPA stimulation, there was a partial shift from the cyto- 
sol to the Triton X-100 soluble fraction. After long-term TPA 
treatment, all forms were down-regulated and the remaining 
antigen was only observed on prolonged exposure of the 
X-ray film and was predominantly in the Triton X-100 in- 
soluble compartment. 
DISCUSSION 
The mutations introduced in the V, domain of PCK-a 
were designed to assess sequence specificity in this domain 
for down-regulation and the role of calpain in TPA-induced 
PKC down-regulation. All three V, mutants were found to 
respond to acute TPA treatment in vivo and were activated 
by TPA (in the presence of phosphatidylserine) in vitro. Simi- 
larly, all three mutants were found to down-regulate in re- 
sponse to TPA. This contrasts with the susceptibility to cleav- 
age by m-calpain where there was a clear hierarchy: p85V, 
> wild-type > V,6, with respect to the rate of cleavage in 
vitro ; V,pz was apparently insensitive to m-calpain cleavage. 
(The susceptibility of the PKC-a p8SV, mutant to m-calpain 
cleavage suggests that this p85a sequence may confer sus- 
ceptibiity in the intact phosphatidylinositol 3-kinase context; 
this has yet to be determined). The implication in this in- 
stance is that m-calpain is not responsible for TPA-induced 
PKC-a down-regulation in vivo, but it remains possible that 
p-calpain may play a role. 
The nature of the mutations made in this study and their 
lack of impact on down-regulation, suggest that no single 
protease with sequence specificity is likely to be involved in 
this process. This would imply that a more general process 
or multiple proteases may be involved in PKC down-regula- 
tion. One such route of proteolysis might be afforded by pro- 
teasome-mediated degradation [ 221 ; alternatively, delivery of 
PKC to lysosomes may be involved. This latter possibility 
would be consistent with a role for PKC in the activation of 
vesicle trafficking (Goode, N., Hajibagheri, N., Warren, G. 
and Parier, P. J.. unpublished results). Since TPA-bound (acti- 
vated) PKC would be membrane associated, it is likely to be 
processed through vesicle-sorting pathways and in this 
context may be targeted for degradation. Although not all 
PKC isotypes may trigger up-regulation of vesicle traffick- 
ing, any isotype capable of binding TPA and becoming mem- 
brane associated could be drawn into a degradative pathway 
passively. This would be consistent with one explanation af- 
forded for the observed down-regulation of a kinase-inactive 
mutant of PCK-a in the context of a cell expressing endoge- 
nous (active) wild-type PCK-a 1231. 
It should be noted that the present data indicate that there 
is no role for m-calpain in the increased proteolysis associ- 
ated with down-regulation. However, it remains possible that 
biological responses to TPA can be mediated by a calpain- 
dependent generation of PKM. Indeed, triggering the 
increased rate of PCK-a mutant degradation described in this 
study could yet be dependent upon calpain-dependent pro- 
teolysis of the endogenous COS cell PKC-a. Such a situation 
might explain the finding that PKC down-regulation can be 
inhibited by a calpain inhibitor [24]. Thus, it can only be 
concluded that the up-regulated pathway of proteolysis does 
not involve calpain and that the means of up-regulation re- 
main obscure. 
In conclusion, the data presented show that m-calpain 
does not appear to be responsible for phorbol-ester-induced 
down-regulation of PCK-a. The data suggest that the speci- 
ficity of the process involved is broader than previously 
thought and, by inference, may involve sorting to a general 
degradative pathway possibly involving the lysosomal com- 
partment. 
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